Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of "Buy" from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has been assigned an average recommendation of "Buy" from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $95.25.

JANX has been the topic of several recent analyst reports. William Blair reissued an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $30.00, for a total value of $100,020.00. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,464,170. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ra Capital Management, L.P. acquired 341,742 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 10,002 shares of company stock worth $348,203. Corporate insiders own 29.40% of the company's stock.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds have recently modified their holdings of JANX. Russell Investments Group Ltd. boosted its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC boosted its holdings in shares of Janux Therapeutics by 1,574.0% in the 1st quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock valued at $45,000 after buying an additional 1,574 shares during the last quarter. FNY Investment Advisers LLC grew its stake in shares of Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock valued at $66,000 after buying an additional 2,425 shares in the last quarter. Finally, KBC Group NV acquired a new position in Janux Therapeutics during the first quarter worth $66,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

JANX traded up $1.18 during trading on Friday, reaching $32.23. 397,710 shares of the company's stock were exchanged, compared to its average volume of 850,966. The company's fifty day moving average price is $30.08 and its 200-day moving average price is $43.08. The firm has a market capitalization of $1.90 billion, a PE ratio of -27.55 and a beta of 3.27. Janux Therapeutics has a fifty-two week low of $22.52 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.